Drugs / BMS-986470
last change Jul 2024 re-read 2 minutes ago

BMS-986470

Developed for
sickle cell disease
Investigated by
Bristol-Myers Squibb

Trials 1 · a red edge is where a trial was stopped

2025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06481306 Jul 2024 → Apr 2028 expected sickle cell disease Bristol-Myers Squibb Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BMS-986470 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06481306